Cyclophosphamide

Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO

Retrieved on: 
Freitag, Mai 31, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Patient, TC, Toxicity, Texas Oncology, Diagnosis, Triple-negative breast cancer, Breast cancer, Gene expression, FLEX, HR, MD, Neoplasm, Taxane, ASCO, Cyclophosphamide, Woman, Breast Cancer Research, Society, Baylor University Medical Center, Quality of life, Medical imaging

Agendia®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL.

Key Points: 
  • Agendia®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL.
  • The FLEX study investigates the 3-year outcome of patients with HR+HER2-, genomically High Risk Luminal B-Type early breast cancer, who have undergone treatment consisting of chemotherapy with taxane and cyclophosphamide (TC) or chemotherapy with anthracycline + TC (AC-T).
  • "The ability to tailor treatment regimens to a patient’s tumor biology is crucial to optimize outcomes and quality of life.
  • MammaPrint's utility in guiding treatment planning is highlighted by these new data evaluating chemotherapy selection," said Dr. O'Shaughnessy.

ImpriMed Launches Innovative AI-Driven Drug Response Predictions (DRP) Service to Guide Tailored Treatments, Meet Rising Demand in Veterinary Oncology

Retrieved on: 
Dienstag, Mai 28, 2024
Technology, Health, Pharmaceutical, Pets, Oncology, Health Technology, Other Science, Artificial Intelligence, Consumer, Science, Veterinary, Doxorubicin, Patient, B-cell lymphoma, Survival, CHOP, Intelligence, Bone marrow, Calendar, Veterinarian, Prednisone, DRP, Lymphoma, AI, Cancer, Leukemia, Medicine, Dog, Cyclophosphamide, Vincristine, Frontiers, Quality of life, Standard of care, Pharmaceutical industry

In response to surging veterinary demand for personalized canine cancer testing, ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the launch of ImpriMed Drug Response Predictions (DRP) .

Key Points: 
  • In response to surging veterinary demand for personalized canine cancer testing, ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the launch of ImpriMed Drug Response Predictions (DRP) .
  • DRP empowers veterinarians with AI-driven clinical outcome predictions for canines with lymphoma and leukemia tailored to individual patient needs, improving efficacy and accelerating patient treatment.
  • Precision diagnostics enable patient-specific cancer therapies upfront, eliminating the need for costly and time-consuming wait-and-see approaches after drug administrations.
  • “We’re thrilled to unveil ImpriMed Drug Response Predictions to fulfill growing customer demand for individualized testing and fundamentally transform clinical approaches to canine cancer treatment.

Panbela Provides Business Update and Reports Q1 2024 Financial Results

Retrieved on: 
Mittwoch, Mai 15, 2024
Doxorubicin, Patient, Doctor of Philosophy, Survival, Neuroblastoma, CPP, PBLA, AACR, Therapy, Overalls, Growth, Research, Topotecan, Note, Acquisition, Cyclophosphamide, Data analysis, Celecoxib, Loss, MSN, DFMO, OTCQB, Pharmaceutical industry

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024.

Key Points: 
  • MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024.
  • Q1 2024 and recent Highlights:
    Announced revised timing for the interim data analysis for its ongoing ASPIRE trial, evaluating ivospemin (SBP-101) in combination with standard-of-care for metastatic pancreatic ductal adenocarcinoma (mPDAC).
  • On the financial and business front, we announced the transfer of our common stock to the OTCQB market and successfully closed a $9.0 million public offering.
  • Net proceeds from the raise, which closed on January 31, 2024, were approximately $8.1 million.

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, Mai 15, 2024
Patient, Cell, Systemic scleroderma, Movement, Lupus, Pemphigus vulgaris, Food, Myopathy, Investment, Letter, CD19, FDA, Disease, MuSK protein, MPV, Conference, Cytokine release syndrome, Dermatology, Congress, Growth, Gene, Immunoglobulin therapy, Potential, Juvenile dermatomyositis, Cyclophosphamide, Dermatomyositis, Symposia, EULAR, IIM, Society, Health Canada, A1, Observation, Research, Clinical trial, DLT, Myositis, Annual general meeting, CRS, Pharmaceutical industry

PHILADELPHIA, May 15, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • PHILADELPHIA, May 15, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • In March 2024, Cabaletta announced the first patient had been dosed in the Phase 1/2 RESET-Myositis trial.
  • Cabaletta expects to report initial clinical data from the Phase 1/2 RESET-SSc™ trial in the second half of 2024.
  • Cabaletta expects to report initial clinical data from the Phase 1/2 RESET-MG™ trial in the second half of 2024.

iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases

Retrieved on: 
Donnerstag, Mai 23, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, European Alliance, Patient, Survival, Lupus, CCAR, Data, Infection, IIT, COVID-19, Class, Patent, T cell, SLE, Clinical trial, CD19, Immunoglobulin M, IND, Safety, Urinary tract infection, Autoantibody, MFR, Cancer, Autoimmunity, Cyclophosphamide, Hospital, EULAR, B cell, BCMA, Glucocorticoid, Canadian Aviation Regulations, LN, Lupus nephritis, CRS, Pharmaceutical industry

The clinical trial evaluated the safety and efficacy of a complete humoral reset of both long-lived plasma cells and B cells in 13 systemic lupus erythematosus (SLE) patients treated with iCell’s cCAR, including 11 patients with SLE and lupus nephritis (LN).

Key Points: 
  • The clinical trial evaluated the safety and efficacy of a complete humoral reset of both long-lived plasma cells and B cells in 13 systemic lupus erythematosus (SLE) patients treated with iCell’s cCAR, including 11 patients with SLE and lupus nephritis (LN).
  • These patients achieved symptom-free and medication-free remission (MFR), with post-cCAR follow-up to 46 months.
  • There are currently no approved therapies that deliver MFR in SLE/LN patients who are at high risk of long-term organ damage and kidney transplant.
  • The data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in SLE and LN patients.

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Retrieved on: 
Dienstag, Mai 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doxorubicin, Patient, Abstract (summary), Lymphoid leukemia, Prednisone, Rituximab, Safety, Congress, EHA, AbbVie, Cyclophosphamide, Abstract, DLBCL, Pharmaceutical industry

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain and virtually, June 13-16, 2024.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain and virtually, June 13-16, 2024.
  • Presentations will include data from clinical trials evaluating the safety and efficacy of epcoritamab as a monotherapy and in combination with standard-of-care or other novel therapies across multiple patient populations.
  • All abstracts accepted for presentation have been published and may be accessed online via the EHA Open Access Library .
  • “Together with AbbVie, we are committed to advancing and evolving the robust development program evaluating epcoritamab, as a monotherapy and in combination, across B-cell malignancies and settings.”
    The safety and efficacy of these investigational uses have not been established.

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024

Retrieved on: 
Dienstag, Mai 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Blood pressure, Diabetes, Patient, Steroid, Hyperlipidemia, Kidney disease, ICER, National Kidney Foundation, Disease, QALY, Glucocorticoid, Cyclophosphamide, MMF, Safety, Physician, Proteinuria, Lupus nephritis, CNI, NKF, Pharmaceutical industry

Economic modeling by the Institute for Clinical and Economic Review (ICER) in March 2021 demonstrated the cost-effectiveness of LUPKYNIS in adults with active lupus nephritis (LN).

Key Points: 
  • Economic modeling by the Institute for Clinical and Economic Review (ICER) in March 2021 demonstrated the cost-effectiveness of LUPKYNIS in adults with active lupus nephritis (LN).
  • An updated cost-effectiveness analysis demonstrated that LUPKYNIS continues to be a cost-effective treatment for lupus nephritis (LN).
  • Cost-effectiveness was assessed with the ICER AnalyticsTM LN model and the majority of model assumptions from the original analysis were consistent with the 2021 analysis.
  • “People living with lupus nephritis must be able to access clinically meaningful treatment options to manage the severity of the disease.

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Retrieved on: 
Donnerstag, Mai 9, 2024
NK, Investment, Lupus nephritis, Safety, Research, Cy, B cell, IND, Autoimmune disease, CD19, Cyclophosphamide, Patient, Cytopenia, NHL, SLE, Lymphoid leukemia, G&A, Investigational New Drug, Pharmaceutical industry

Nkarta expects to provide an update on first patient dosing for NKX019 in LN in the first half of 2024.

Key Points: 
  • Nkarta expects to provide an update on first patient dosing for NKX019 in LN in the first half of 2024.
  • In March 2024, Nkarta completed an underwritten offering of common stock and pre-funded warrants with gross proceeds of $240.1 million.
  • Nkarta had cash, cash equivalents, restricted cash, and investments in marketable securities of $450.0 million as of March 31, 2024.
  • Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024.

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

Retrieved on: 
Donnerstag, Mai 9, 2024
Research, FDA, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Congress, Glucocorticoid, Safety, Patient, Kidney, Lupus nephritis, Proteinuria, CNI, EULAR, Rheumatology, Steroid, Cyclophosphamide, Comparison, CCR, Standard of care, MMF, Pharmaceutical industry

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in Destin, FL, May 9-12.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in Destin, FL, May 9-12.
  • The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), in combination with MMF and steroids, for the treatment of adult patients with active lupus nephritis (LN), as shown in the AURORA Clinical Program.
  • Safety and efficacy outcomes for propensity-matched patients with active LN from the AURA-LV plus AURORA 1 studies were assessed at three and six months.
  • “Early reduction in proteinuria after initial treatment has been associated with improved long-term kidney outcomes in lupus nephritis,” said Dr. Greg Keenan, Chief Medical Officer of Aurinia.

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis

Retrieved on: 
Mittwoch, April 17, 2024
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Patient, Lupus nephritis, Nephritis, Safety, Lupus Research Alliance, Tissue, CD20, CD38, Lupus, Rituximab, Autoimmune disease, CD19, Cyclophosphamide, LN, NHL, Immune system, Clinical trial, Therapy, NK, Network, UC

AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.

Key Points: 
  • AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.
  • To our knowledge, this is the first time a patient has received an allogeneic NK cell therapy candidate in a U.S. clinical trial for treatment of an autoimmune disease.
  • Artiva is collaborating with Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, to support the evaluation of AlloNK for LN.
  • The Network, overseen by Lupus Therapeutics, is comprised of leading research centers throughout North America with the purpose of accelerating and optimizing lupus clinical trials.